Women on PEDs: Bloodwork Differences Every Female Athlete Needs to Know

The female endocrine system operates on a roughly 28-day cycle driven by estrogen and progesterone. This is not a trivial detail — these hormones directly affect your blood work. Estrogen stimulates SHBG production in the liver, increases cortisol-binding globulin, and influences thyroid-binding globulin. When you introduce exogenous androgens, you disrupt this entire regulatory system.

Women naturally have higher SHBG than men because estrogen upregulates hepatic SHBG synthesis. This means a given dose of AAS has different free-androgen dynamics in women — more of the compound gets bound, which can both reduce efficacy and alter the side effect profile. When AAS suppress SHBG (and they do, universally), the effect is more pronounced because you start from a higher baseline.

Endogenous hormone production is also different. Women produce small amounts of testosterone (about 15–70 ng/dL) and androstenedione from the ovaries and adrenal glands. When you add exogenous AAS, endogenous production shuts down, but the clinical consequences of suppression are less immediately apparent than in men — no dramatic drop in libido or erectile function to signal the need for blood work.

The single most underappreciated variable in female blood work is cycle timing. Your menstrual phase at the time of the draw can shift values by 10–20% for several critical markers. Ignoring this makes your results essentially uninterpretable — you are comparing a luteal-phase blood panel to follicular-phase reference ranges and wondering why things look off.

Here is what changes across the cycle and why timing matters:

The practical takeaway: draw in the follicular phase, ideally between days 3 and 10 of your cycle. This gives you the most consistent, reproducible baseline. If you draw in the luteal phase, note it — and interpret TSH, iron, and glucose with the understanding that they will naturally be shifted.

📅

A TSH measured in the luteal phase can be 1.5–2.0 mIU/L higher than the same person's follicular-phase value — enough to push a normal result into the subclinical hypothyroidism range.

— Clinical Endocrinology Review

Compound choices for women are more limited than for men, and the monitoring requirements are different. The key principle: androgenicity drives both the desired effects and the risks, and women are more sensitive to androgenic activity at every dose level. A dose that produces mild lipid changes in a man can cause significant virilization in a woman — and the threshold varies between individuals based on genetics, SHBG levels, and androgen receptor sensitivity.

Here is a breakdown of the most commonly used compounds with female-specific dosing and monitoring guidance:

Key dosing principles for women:

• Start low, go slow — Begin at the lowest effective dose and titrate up over weeks, not days. The androgenic threshold is individual, and crossing it produces side effects that are not always reversible.
• Short esters first — Choose compounds with shorter half-lives (testosterone propionate over enanthate, nandrolone phenylpropionate over decanoate). If virilization signs appear, shorter esters clear faster and the side effect progression stops sooner.
• Single compound cycles — Avoid stacking multiple AAS as a first-time user. A single compound at a moderate dose allows you to isolate effects and identify your individual tolerance before considering more complex protocols.
• Cycle length matters — Female AAS cycles are typically shorter than male cycles (6–8 weeks versus 12–20 weeks). The risk of androgenic side effects increases with cumulative exposure time, not just dose.

Regular blood work for female AAS users should include: total testosterone, free testosterone (or calculated free T), SHBG, estradiol, LH, FSH, complete lipid profile (total cholesterol, HDL, LDL, triglycerides, ApoB), liver enzymes (AST, ALT, GGT), ferritin, iron panel, TSH, free T4, free T3, and CBC. This is a broader panel than most male users order — and it should be, because the interactions between AAS, the menstrual cycle, and female endocrinology are more complex.

Voice changes are the most psychologically impactful and least reversible androgenic side effect of AAS use in women. Unlike clitoral enlargement (which may partially regress after compound cessation) or increased body hair (which can be managed cosmetically), voice deepening is permanent once threshold damage occurs. The vocal folds (vocal cords) are androgen-sensitive tissue with high concentrations of androgen receptors. When exposed to supraphysiological androgen levels, they thicken and elongate — and unlike muscle tissue, they do not revert to baseline when the stimulus is removed.

The challenge for monitoring is that voice changes are subjective and gradual. You generally do not notice your voice changing while it is happening — it is other people who notice first. By the time you feel vocal roughness, hoarseness, or a reduced upper vocal range, the structural changes may already be established. This makes objective monitoring tools critical.

Blood markers that correlate with vocal virilization risk:

• Free Androgen Index (FAI): The strongest blood-based predictor. A FAI above 10 in women correlates with a marked increase in androgenic side effects, including vocal changes. Tracking FAI monthly allows you to see the trajectory before symptoms emerge.
• Free testosterone (calculated or direct): Free T above 10–15 ng/dL in women is a warning zone where vocal changes become more likely. The absolute threshold varies, but the rate of change matters — a rapid rise over 4–6 weeks is more dangerous than a gradual increase over months.
• SHBG: Low SHBG (below 20 nmol/L) frees up more androgen to interact with vocal fold tissue. A dropping SHBG trend, even if free T looks stable, should be taken as a warning signal.
• DHT (dihydrotestosterone): The most potent androgen for vocal fold thickening. If you are using compounds that convert to DHT (testosterone, Anavar) or that are DHT derivatives (Winstrol, Primobolan, Masteron), DHT levels provide specific information about androgenic load on vocal tissue.

Practical voice monitoring protocol:

• Voice journaling: Record a 30-second voice sample weekly (same phrase, same time of day, same recording device). Play back week-over-week to detect subtle changes. Apps like Vocal Pitch Monitor (available on iOS/Android) provide objective frequency tracking. A drop in habitual speaking pitch of more than 20–30 Hz is a warning sign.
• Symptom checklist: Weekly self-check: Do you clear your throat more often? Does your voice tire faster by the end of the day? Have others commented on your voice? Has your singing range narrowed? Any "yes" warrants investigation.
• Blood work correlation: At the first sign of voice change, check total testosterone, free testosterone, SHBG, DHT, and FAI. If free T has doubled from baseline or FAI has crossed 10, consider dose reduction or compound discontinuation.
• Irreversibility awareness: Voice changes from short-term AAS exposure (4–6 weeks) may partially reverse, but changes from cycles lasting 12+ weeks at androgenic doses are typically permanent. The "safe window" for vocal fold recovery is narrower than you think.

Women start with lower iron stores than men. The average premenopausal woman has ferritin levels of 30–60 ng/mL, compared to 100–300 ng/mL in men. This is a direct consequence of menstrual blood loss — approximately 10–40 mL of blood per cycle, carrying 1–3 mg of iron.

When you add AAS into this equation, the iron picture becomes even more complex. AAS stimulate erythropoiesis (red blood cell production), which increases iron demand. Your bone marrow needs more iron to build more RBCs. Combined with dietary restriction (common in contest prep), reduced iron intake, and potential menstrual changes (some women experience suppression of menstruation on AAS, others do not), ferritin can drop rapidly.

The depletion timeline is faster than most athletes realize. A female athlete with baseline ferritin of 50 ng/mL who starts AAS, trains hard, and restricts calories can drop to below 20 ng/mL within 8–12 weeks. Symptoms — fatigue, poor recovery, heavy legs, brain fog — are often attributed to training load or AAS side effects when the real cause is iron depletion.

Blood donation adds another layer of risk. Phlebotomy for hematocrit management removes 200–250 mg of iron per donation. For a woman with already low iron stores, a single donation can push ferritin into single digits. The female AAS user who donates blood should be monitored with ferritin levels every 4–6 weeks, and iron supplementation should be considered if ferritin drops below 30 ng/mL.

Thyroid dysfunction is 5 to 10 times more common in women than in men. Autoimmune thyroid conditions (Hashimoto's, Graves') have a strong female predominance, and the interaction between AAS, thyroid function, and female endocrinology is poorly understood by most coaches and clinicians.

AAS affect the thyroid at multiple levels. Androgens reduce thyroxine-binding globulin (TBG), which affects measured total T4 and T3 without necessarily altering free hormone levels. This can create the appearance of thyroid dysfunction — low total T4, normal TSH, normal free T4 — that is actually a harmless binding-protein shift. But it can also unmask subclinical thyroid disease that was previously compensated.

The practical recommendation: include TSH, free T4, and free T3 in every baseline and follow-up blood panel. If TSH is above 2.5 mIU/L, add anti-TPO and anti-thyroglobulin antibodies to screen for Hashimoto's. AAS-related TBG suppression can mask Hashimoto's by lowering total T4 while free T4 remains normal — the antibody tests catch what the standard panel misses.

Women naturally have higher HDL cholesterol than men — typically 50–70 mg/dL versus 40–55 mg/dL. This is one of the reasons premenopausal women have lower cardiovascular event rates than age-matched men. Estrogen upregulates ApoA1 production (the primary protein in HDL particles), resulting in more and better-functioning HDL.

When women use AAS, the absolute HDL drop is more dramatic than in men — not because the compounds are more toxic to lipids in women, but because the starting point is higher. A female athlete whose HDL drops from 65 to 35 mg/dL on Anavar has experienced a 46% reduction. A male athlete dropping from 50 to 35 mg/dL has experienced a 30% reduction. The absolute endpoint (35 mg/dL) is the same, but the physiological context is different.

The key insight: the absolute HDL value on AAS matters more than the percentage drop. An HDL of 35 mg/dL is low regardless of whether you started at 65 or 50. But the faster rate of decline in women is worth monitoring more frequently — quarterly lipid panels during cycle, not just at the start and end.

ApoB remains the most important advanced lipid marker for women on AAS, just as it is for men. An ApoB below 100 mg/dL with HDL above 30 mg/dL is a manageable cardiovascular risk profile. But the ApoB/ApoA1 ratio may be a particularly informative metric for women, since ApoA1 (driven by estrogen) drops more sharply in female AAS users.

Bone density is regulated by a complex interplay of estrogen, androgens, mechanical loading, and calcium metabolism. For female athletes, AAS have a dual effect: the androgens promote bone formation (a positive effect), but menstrual suppression from AAS reduces estrogen's bone-protective effect (a negative effect).

The net effect depends on compound choice, dose, and cycle length. Mild compounds at moderate doses (Anavar 10–15 mg/day) may preserve menstrual function while still providing anabolic bone benefits. Higher androgen doses or stacked compounds are more likely to suppress menstruation, reducing estrogen's contribution to bone density maintenance.

Blood markers to monitor for bone health:

• Calcium: Total and corrected calcium (albumin-adjusted) — AAS can alter albumin levels, making corrected calcium more accurate than total calcium alone. Ionized calcium (free, unbound calcium) is even more precise but rarely covered by standard panels.
• Vitamin D (25-OH): Maintain above 50 nmol/L, ideally above 75 nmol/L for athletes. Vitamin D status affects calcium absorption and bone turnover. Female athletes are more likely than male athletes to be vitamin D deficient, especially if training indoors or living at northern latitudes. Supplement with 2,000–4,000 IU/day of vitamin D3 if levels are below 50 nmol/L.
• PTH (Parathyroid Hormone): Elevated PTH suggests calcium or vitamin D insufficiency. PTH can rise when AAS alter calcium metabolism or when calcium intake is low. Sustained PTH elevation is catabolic to bone — it signals your body is pulling calcium from the skeleton to maintain blood calcium levels. If PTH is elevated despite adequate vitamin D and calcium intake, investigate further (calcium absorption issues, renal function, or primary hyperparathyroidism).
• Estradiol: If menstrual suppression occurs, estradiol below 50 pg/mL for extended periods (6+ months) raises bone density concerns. This is a female-specific consideration that male AAS users never have to think about. Estradiol's role in bone health is so significant that the Women's Health Initiative (a landmark study published in JAMA) showed that estrogen therapy reduced hip fracture risk by 34% in postmenopausal women — a dramatic effect that underscores what is at stake when estrogen is suppressed.
• Bone turnover markers (advanced): For athletes with prolonged amenorrhea (12+ months) or a family history of osteoporosis, consider adding bone turnover markers: CTX (C-terminal telopeptide, a bone resorption marker) and P1NP (procollagen type 1 N-terminal propeptide, a bone formation marker). An elevated CTX with normal or low P1NP indicates bone loss exceeding bone formation — a red flag that warrants intervention. These markers are not part of standard panels and must be ordered separately, but they provide the earliest objective evidence of AAS-related bone density changes, years before a DEXA scan would detect them.

Calcium intake becomes more critical during AAS use because the combination of increased bone turnover (from androgens) and potential estrogen suppression (from menstrual disruption) creates higher calcium demand. Female athletes using AAS should aim for 1,200–1,500 mg of total daily calcium from diet and supplementation combined — higher than the general recommendation of 1,000 mg. Dairy, calcium-set tofu, fortified plant milks, and sardines with bones are the most bioavailable sources. Calcium carbonate supplements are adequate if taken with food; calcium citrate is preferable for those on proton pump inhibitors or with reduced stomach acid.

AAS are contraindicated during pregnancy — not just because of potential virilization of a female fetus (which is the most commonly cited concern), but because AAS disrupt the entire hormonal cascade required for conception, implantation, and early gestation. Planning a pregnancy while using AAS requires a deliberate, structured cessation and recovery protocol that is fundamentally different from a standard post-cycle plan.

The fertility challenge: AAS suppress the hypothalamic-pituitary-ovarian (HPO) axis, reducing LH and FSH production. Without adequate FSH, follicular development does not occur. Without adequate LH, ovulation does not occur. This creates anovulatory cycles — cycles in which no egg is released — making conception impossible. Unlike men, who produce sperm continuously (and can often restore fertility with HCG or clomiphene), women must restore a complete ovulatory cycle, which depends on intricate timing of FSH, LH, estradiol, and progesterone signaling over 4–6 weeks per cycle.

The recommended cessation timeline:

Here is the complete monitoring protocol for female AAS users, combining everything covered above into a practical schedule: